Management of the upper gastrointestinal adverse effect of non-steroid anti-inflammatory drugs

Guo Jin-sheng
DOI: https://doi.org/10.3969/j.issn.1672-3384.2012.03.002
2012-01-01
Abstract:Non-steroid anti-inflammatory drugs (NSAIDs) is a group of commonly prescribed drugs with anti-inflammatory, analgesic, antipyretic properties. They all have an effect on inhibiting cyclooxygenase (COX) activity and blocking inflammatory prostaglandins synthesis. Based on their selectivity on COX isoenzymes, they were categorized into non-selective COX inhibitors, selective and highly selective COX-2 inhibitors. The clinical usage of NSAIDs may induce gastrointestinal adverse effect to varying degrees, and is one of the major causes of peptic ulcer and upper gastrointestinal bleeding in the patients, especially the high-risk population. In addition, some of the NSAIDs may increase the risk of cardiovascular events including acute myocardial infarction and stroke. The selection of NSAIDs and the prevention of their adverse effects have significant clinical and economic importance. NSAIDs should be administrated to appropriate and obligatory patients, with the minimum dosage and duration, and avoid being used in combination. Long-term administration should be limited to those patients that intolerant to other types of analgesia and compliant with frequent follow-up. For those patients with high risk of gastrointestinal adverse effects of NSAIDs, the selection of drugs should refer to current guideline for NSAIDs use and take preventing measures.
What problem does this paper attempt to address?